These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 23278714)

  • 1. Evaluating the use of the interferon-γ response to Mycobacterium tuberculosis-specific antigens in patients with psoriasis prior to antitumour necrosis factor-α therapy: a prospective head-to-head cross-sectional study.
    Martyn-Simmons CL; Mee JB; Kirkham BW; Groves RW; Milburn HJ
    Br J Dermatol; 2013 May; 168(5):1012-8. PubMed ID: 23278714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
    Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
    Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.
    Ponce de Leon D; Acevedo-Vasquez E; Alvizuri S; Gutierrez C; Cucho M; Alfaro J; Perich R; Sanchez-Torres A; Pastor C; Sanchez-Schwartz C; Medina M; Gamboa R; Ugarte M
    J Rheumatol; 2008 May; 35(5):776-81. PubMed ID: 18398944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
    Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
    Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy.
    Sellam J; Hamdi H; Roy C; Baron G; Lemann M; Puéchal X; Breban M; Berenbaum F; Humbert M; Weldingh K; Salmon D; Ravaud P; Emilie D; Mariette X;
    Ann Rheum Dis; 2007 Dec; 66(12):1610-5. PubMed ID: 17456528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results.
    Costantino F; de Carvalho Bittencourt M; Rat AC; Loeuille D; Dintinger H; Béné MC; Faure G; Chary-Valckenaere I
    J Rheumatol; 2013 Dec; 40(12):1986-93. PubMed ID: 24085550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study.
    Garcovich S; Ruggeri A; D'Agostino M; Ardito F; De Simone C; Delogu G; Fadda G
    J Eur Acad Dermatol Venereol; 2012 Dec; 26(12):1572-6. PubMed ID: 21923840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test.
    Laffitte E; Janssens JP; Roux-Lombard P; Thielen AM; Barde C; Marazza G; Panizzon RG; Saurat JH
    Br J Dermatol; 2009 Oct; 161(4):797-800. PubMed ID: 19659473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevalence of latent infection with Mycobacterium tuberculosis in Mazovia Region using interferon gamma release assay after stimulation with specific antigens ESAT-6 and CFP-10].
    Kuś J; Demkow U; Lewandowska K; Korzeniewska-Koseła M; Rabczenko D; Siemion-Szcześniak I; Białas-Chromiec B; Bychawska M; Sapigórski P; Maciejewski J
    Pneumonol Alergol Pol; 2011; 79(6):407-18. PubMed ID: 22028119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients.
    Triverio PA; Bridevaux PO; Roux-Lombard P; Niksic L; Rochat T; Martin PY; Saudan P; Janssens JP
    Nephrol Dial Transplant; 2009 Jun; 24(6):1952-6. PubMed ID: 19164327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
    Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
    Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases.
    Soborg B; Ruhwald M; Hetland ML; Jacobsen S; Andersen AB; Milman N; Thomsen VO; Jensen DV; Koch A; Wohlfahrt J; Ravn P
    J Rheumatol; 2009 Sep; 36(9):1876-84. PubMed ID: 19648300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of QuantiFERON-TB Gold test and tuberculin skin test for the identification of latent Mycobacterium tuberculosis infection in lupus patients.
    Yilmaz N; Zehra Aydin S; Inanc N; Karakurt S; Direskeneli H; Yavuz S
    Lupus; 2012 Apr; 21(5):491-5. PubMed ID: 22140142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions.
    Kleinert S; Tony HP; Krueger K; Detert J; Mielke F; Rockwitz K; Schwenke R; Burmester GR; Diel R; Feuchtenberger M; Kneitz C
    Ann Rheum Dis; 2012 Nov; 71(11):1791-5. PubMed ID: 22586160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.
    Vassilopoulos D; Stamoulis N; Hadziyannis E; Archimandritis AJ
    J Rheumatol; 2008 Jul; 35(7):1271-6. PubMed ID: 18381793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
    Hsia EC; Schluger N; Cush JJ; Chaisson RE; Matteson EL; Xu S; Beutler A; Doyle MK; Hsu B; Rahman MU
    Arthritis Rheum; 2012 Jul; 64(7):2068-77. PubMed ID: 22238071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Update of the guidelines of the Israeli Association of Rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
    Balbir-Gurman A; Lidgi M; Elkayam O
    Harefuah; 2014 Jun; 153(6):359-61, 366. PubMed ID: 25095612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cells co-producing Mycobacterium tuberculosis-specific type 1 cytokines for the diagnosis of latent tuberculosis.
    Nemeth J; Winkler HM; Karlhofer F; Selenko-Gebauer N; Graninger W; Winkler S
    Eur Cytokine Netw; 2010 Mar; 21(1):34-9. PubMed ID: 20146988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordance of two interferon-γ release assays and tuberculin skin test in patients with uveitis.
    Ang M; Kiew SY; Wong WL; Chee SP
    Br J Ophthalmol; 2014 Dec; 98(12):1649-53. PubMed ID: 25001322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
    Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
    Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.